Nasus Pharma (NSRX) Enterprise Value (2024 - 2025)
Nasus Pharma (NSRX) reported Enterprise Value of -$4.3 million for Q4 2025, down 1409.15% on a YoY basis from $327386.8 in Q4 2024, and down 1747.41% quarter-over-quarter from -$232000.0 in Q2 2025.
Nasus Pharma (NSRX) Enterprise Value (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Enterprise Value for 2 years, with the latest figure at -$4.3 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 1409.15% year-over-year to -$4.3 million; the trailing twelve-month figure through Dec 2025 stood at -$4.3 million (down 1409.15% YoY), and the FY2025 full-year result was -$4.3 million, down 1409.15% from the prior year.
- Enterprise Value for Q4 2025 stood at -$4.3 million, down from -$232000.0 in the prior quarter.
- The five-year high for Enterprise Value was -$232000.0 in Q2 2025, with the low at -$4.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | -4.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.29 Mn |
| Jun 30, 2025 | -232,000.00 |
| Dec 31, 2024 | -284,000.00 |